Skip to main content
Premium Trial:

Request an Annual Quote

ProMetic Life Sciences Grosses $6.4M From Stock Placement

NEW YORK (GenomeWeb News) — ProMetic Life Sciences has closed CA$6.6 million ($6.4 million) by selling 18.9 million subordinate shares for CA$.35 a share, the Montreal-based company said Tuesday.
 
ProMetic said it issued 13.3 million shares to Paradigm Capital for CA$4.7 million and 5.5 million shares to unidentified US institutional investors for CA$1.9 million.
 
Rodman & Renshaw Capital Group served as financial advisers for the financing, the company said.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.